Biotech Values

[oc631]

What else does Roche have in the HCV space to pair with a non-nuke?

Roche has RG7432 which is a nucleotide inhibitor in phase 1. If this nuke falls short in efficacy as a mono-therapy maybe setrobuvir would be a safe DAA addition? Safety and its mid-stage status are the only two desirable aspects I see to the drug. I doubt danoprevir and mericitabine will be used with setrobuvir and I would consider this part of the rebirth of Roche's HVC program.